Differences in IGFBP-3 regulation between young healthy women from BRCAX families and those belonging to BRCA1/2 families

European Journal of Cancer Prevention

Volumn 15, Issue 3, 2006, Pages 233-241

  Jernström, Helena ^a   Sellberg, Gunilla ^a   Borg, Åke ^a   Olsson, Håkan ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

BRCA1; BRCA2; BRCAX; IGF1 genotype; IGFBP3 genotype; Insulin like growth factor binding protein 3; Insulin like growth factor 1

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; ORAL CONTRACEPTIVE AGENT; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 3;

ADULT; ALLELE; ARTICLE; BODY HEIGHT; BODY WEIGHT; BREAST CANCER; CANCER RISK; DRUG USE; FAMILIAL CANCER; FEMALE; GENE FREQUENCY; GENE MUTATION; GENETIC ASSOCIATION; GENETIC DIFFERENCE; GENOTYPE; HUMAN; MENSTRUAL CYCLE; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUESTIONNAIRE; REGULATORY MECHANISM; REPRODUCTION;

ADULT; AGE FACTORS; BODY SIZE; BREAST NEOPLASMS; CONTRACEPTION; FAMILY; FEMALE; GENES, BRCA1; GENES, BRCA2; GENOTYPE; GERM-LINE MUTATION; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; MENSTRUAL CYCLE; NEOPLASTIC SYNDROMES, HEREDITARY; POLYMORPHISM, GENETIC; REPRODUCTION;

EID: 33646915496     PISSN: 09598278     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cej.0000203615.77183.97     Document Type: Article

References (44)

1. Anderson H, Bladström A, Olsson H, Möller TR (2000). Familial breast and ovarian cancer: a Swedish population-based register study. Am J Epidemiol 152:1154-1163.
2. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, et al. (2003). Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72:1117-1130.
3. Bang P, Eriksson U, Sara V, Wivall IL, Hall K (1991). Comparison of acid ethanol extraction and acid gel filtration prior to IGF-I and IGF-II radioimmunoassays: improvement of determinations in acid ethanol extracts by the use of truncated IGF-I as radioligand. Acta Endocrinol (Copenhagen) 124:620-629.
4. Bohlke K, Cramer DW, Trichopoulos D, Mantzoros CS (1998). Insulin-like growth factor-I in relation to premenopausal ductal carcinoma in situ of the breast. Epidemiology 9:570-573.
5. Boyd NF, Lockwood GA, Byng JW, Tritchler DL, Yaffe MJ (1998). Mammographic densities and breast cancer risk. Cancer Epidemiol Biomarkers Prev 7:1133-1144.
6. Byrne C, Colditz GA, Willett WC, Speizer FE, Pollak M, Hankinson SE (2000). Plasma insulin-like growth factor (IGF) I, IGF-binding protein 3, and mammographic density. Cancer Res 60:3744-3748.
7. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, et al. (1998). Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 279:563-566.
8. Cohen SM, Ellwein LB (1990). Cell proliferation in carcinogenesis. Science 249:1007-1011.
9. Dabrosin C (2003). Increase of free insulin-like growth factor-1 in normal human breast in vivo late in the menstrual cycle. Breast Cancer Res Treat 80:193-198.
10. Deal C, Ma J, Wilkin F, Paquette J, Rozen F, Ge B, et al. (2001). Novel promoter polymorphism in insulin-like growth factor-binding protein-3: correlation with serum levels and interaction with known regulators. J Clin Endocrinol Metab 86:1274-1280.
11. Easton DF, Ford D, Bishop DT (1995). Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet 56:265-271.
12. Gregoraszczuk EL, Milewicz T, Kolodziejczyk J, Krzysiek J, Basta A, Sztefko K, et al. (2001). Progesterone-induced secretion of growth hormone, insulin-like growth factor I and prolactin by human breast cancer explants. Gynecol Endocrinol 15:251-258.
13. Gronbaek H, Flyvbjerg A, Mellemkjaer L, Tjonneland A, Christensen J, Toft Sorensen H, et al. (2004). Serum insulin-like growth factors, insulin-like growth factor binding proteins, and breast cancer risk in postmenopausal women. Cancer Epidemiol Biomarkers Prev 13:1759-1764.
14. Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, et al. (1998). Circulating concentrations of insulin-like growth factor-1 and risk of breast cancer. Lancet 351:1393-1396.
15. Harrela M, Koistinen H, Kaprio J, Lehtovirta M, Tuomilehto J, Eriksson J, et al. (1996). Genetic and environmental components of interindividual variation in circulating levels of IGF-I, IGF-II, IGFBP-1, and IGFBP-3. J Clin Invest 98:2612-2615.
16. Huo Z, Giger ML, Olopade OI, Wolverton DE, Weber BL, Metz CE, et al. (2002). Computerized analysis of digitized mammograms of BRCA1 and BRCA2 gene mutation carriers. Radiology, 225:519-526.
17. Jernström H, Deal C, Wilkin F, Chu W, Tao Y, Majeed N, et al. (2001). Genetic and non-genetic factors associated with variation of plasma levels of insulin-like growth factor-I and insulin-like growth factor binding protein-3 in healthy premenopausal women. Cancer Epidemiol Biomarkers Prev 10:377-384.
18. Juul A, Bang P, Hertel NT, Main K, Dalgaard P, Jorgensen K, et al. (1994a). Serum insulin-like growth factor-I in 1030 healthy children, adolescents, and adults: relation to age, sex, stage of puberty, testicular size, and body mass index. J Clin Endocrinol Metab 78:744-752.
19. Juul A, Dalgaard P, Blum WF, Bang P, Hall K, Michaelsen KF (1994b). The ratio between serum levels of insulin-like growth factor (IGF)-I and the IGF binding proteins (IGFBP-1, 2 and 3) decreases with age in healthy adults and is increased in acromegalic patients. Clin Endocrinol (Oxford) 41:85-93.
20. Juul A, Dalgaard P, Blum WF, Bang P, Hall K, Michaelsen KF, et al. (1995). Serum levels of insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) in healthy infants, children, and adolescents: the relation to IGF-I, IGF-II, IGFBP-1, IGFBP-2, age, sex, body mass index, and pubertal maturation. J Clin Endocrinol Metab 80:2534-2542.
21. Kao PC, Matheny AP Jr, Lang CA (1994). Insulin-like growth factor-I comparisons in healthy twin children. J Clin Endocrinol Metab 78:310-312.
22. Krzysiek J, Milewicz T, Augustowska K, Sztefko K, Rys J, Zubel A, et al. (2003). The impact of progesterone on simultaneous, local secretion of IGFBP-3 and IGF-I [IGFBP-3/IGF-I index] by human malignant and non-malignant breast explants depends on tissue steroid receptor phenotype. Ginekol Pol 74:767-774.
23. Lahmann PH, Hoffmann K, Allen N, van Gils CH, Khaw KT, Tehard B, et al. (2004). Body size and breast cancer risk: findings from the European Prospective Investigation into Cancer And Nutrition (EPIC). Int J Cancer 111:762-771.
24. Lai JH, Vesprini D, Zhang W, Yaffe MJ, Pollak M, Narod SA (2004). A polymorphic locus in the promoter region of the IGFBP3 gene is related to mammographic breast density. Cancer Epidemiol Biomarkers Prev 13:573-582.
25. Loman N, Johannsson O, Bendahl P-O, Borg Å, Fernö M, Olsson H (1998). Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes. Cancer 83:310-319.
26. Ma J, Pollak MN, Giovannucci E, Chan JM, Tao Y, Hennekens CH, et al. (1999). Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3 [see comments]. J Natl Cancer Inst 91:620-625.
27. McCarty KS Jr, Silva JS, Cox EB, Leight GS Jr, Wells SA Jr, McCarty KS Sr (1983). Relationship of age and menopausal status to estrogen receptor content in primary carcinoma of the breast. Ann Surg 197:123-127.
28. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshmann K, Tavtigian S, et al. (1994). A strong candidate for breast and ovarian cancer susceptibility gene BRCA1. Science 266:66-71.
29. Nathanson KL, Weber BL (2001). 'Other' breast cancer susceptibility genes: searching for more holy grail. Hum Mol Genet 10:715-720.
30. Olsson H (2001). A hypothesis about tumour development and the clinical features of hereditary breast cancers. Eur J Cancer 37:2023-2029.
31. Preston-Martin S, Pike MC, Ross RK, Jones PA, Henderson BE (1990). Increased cell division as a cause of human cancer. Cancer Res 50:7415-7421.
32. Ren Z, Cai Q, Shu XO, Cai H, Li C, Yu H, et al. (2004). Genetic polymorphisms in the IGFBP3 gene: association with breast cancer risk and blood IGFBP-3 protein levels among Chinese women. Cancer Epidemiol Biomarkers Prev 13:1290-1295.
33. Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M (2004). Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 363:1346-1353.
34. Rohrbacher M, Risch A, Kropp S, Chang-Claude J (2005). The A(-336C) insulin-like growth factor binding protein-3 promoter polymorphism is not a modulator of breast cancer risk in Caucasian women. Cancer Epidemiol Biomarkers Prev 14:289-290.
35. Shi R, Yu H, McLarty J, Glass J (2004). IGF-I and breast cancer: a meta-analysis. Int J Cancer 111:418-423.
36. Stewart CE, Rotwein P (1996). Growth, differentiation, and survival: multiple physiological functions for insulin-like growth factors. Physiol Rev 76:1005-1026.
37. Sugumar A, Liu YC, Xia Q, Koh YS, Matsuo K (2004). Insulin-like growth factor (IGF)-I and IGF-binding protein 3 and the risk of premenopausal breast cancer: a meta-analysis of literature. Int J Cancer 111:293-297.
38. Swerdlow AJ, De Stavola BL, Floderus B, Holm NV, Kaprio J, Verkasalo PK, et al. (2002). Risk factors for breast cancer at young ages in twins: an international population-based study. J Natl Cancer Inst 94:1238-1246.
39. Tonin P, Ghadirian P, Phelan C, Lenoir GM, Lynch HT, Letendre F, et al. (1995). A large multisite cancer family is linked to BRCA2. J Med Genet 32:982-984.
40. Vatten LJ, Kvinnsland S (1990). Body mass index and risk of breast cancer. A prospective study of 23,826 Norwegian women. Int J Cancer 45:440-444.
41. Weiderpass E, Braaten T, Magnusson C, Kumle M, Vainio H, Lund E, et al. (2004). A prospective study of body size in different periods of life and risk of premenopausal breast cancer. Cancer Epidemiol Biomarkers Prev 13:1121-1127.
42. Willett WC, Browne ML, Bain C, Lipnick RJ, Stampfer MJ, Rosner B, et al. (1985). Relative weight and risk of breast cancer among premenopausal women. Am J Epidemiol 122:731-740.
43. Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, et al. (1995). Identification of the breast cancer susceptibility gene BRCA2. Nature 378:789-792.
44. Yakar S, Liu JL, Stannard B, Butler A, Accili D, Sauer B, et al. (1999). Normal growth and development in the absence of hepatic insulin-like growth factor I. Proc Natl Acad Sci U S A 96:7324-7329.